The Goldman Sachs Group Cuts Moderna (NASDAQ:MRNA) Price Target to $99.00

Moderna (NASDAQ:MRNA) had its target price decreased by The Goldman Sachs Group from $112.00 to $99.00 in a research report sent to investors on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

MRNA has been the topic of a number of other reports. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. UBS Group dropped their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Jefferies Financial Group dropped their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. Finally, Morgan Stanley cut their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $67.26.

Moderna Trading Up 0.8 %

Shares of MRNA stock opened at $41.04 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The firm has a fifty day moving average of $40.87 and a 200-day moving average of $62.03. Moderna has a 52-week low of $31.94 and a 52-week high of $170.47. The stock has a market cap of $15.79 billion, a price-to-earnings ratio of -7.05 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the business posted ($1.39) earnings per share. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, equities research analysts forecast that Moderna will post -9.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. Insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Large investors have recently modified their holdings of the business. Blue Trust Inc. grew its position in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares during the period. Wilmington Savings Fund Society FSB boosted its holdings in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Larson Financial Group LLC increased its position in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after acquiring an additional 317 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after acquiring an additional 778 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its position in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.